Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.
about
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseAssessment of joint and fascia manifestations in chronic graft-versus-host disease.Current issues in chronic graft-versus-host disease.Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.How we treat chronic graft-versus-host disease.Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host DiseaseA Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host diseaseJoint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters.Cutaneous manifestations of graft-versus-host disease: role of the dermatologist.Genetic risk factors for sclerotic graft-versus-host disease.Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions.Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.[Cutaneous graft-versus-host disease].Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
P2860
Q28076264-2F7FB7A4-D5DF-4B53-B23A-EE3C1A57BAA7Q33583436-8BCC58F5-8649-4A6F-B11B-FD48A3E98919Q33917187-389A5B98-489E-4FBF-85CA-B3C94C084ABFQ34860985-CFB39CE5-6F58-4797-AAFA-FE19FD0CDD3CQ35004923-E5AAEEEE-A2A1-4037-B7E1-9FC0C3937F31Q35571058-4C0F8533-F064-42E8-9E1A-22E04B5552CBQ36220062-E885839F-7594-4AE5-B9FE-A2F9F7B28A4AQ36471247-B22DDAD0-E665-4CE1-A07D-54A4B76237A2Q36675947-62DE91CA-291F-4B99-AAD0-C43B97A18957Q36708947-DDDCFAF5-B23E-4073-B5F9-1C1086226754Q37075998-6D40550B-4501-4059-A1C0-736D6772C4D9Q37076010-E3A2B77A-D341-4C2E-9D39-6D6DF87C9B32Q38961868-BADB310A-D9FA-42A7-9D6C-83859CB66957Q41108286-040EBE86-723A-437D-89D8-C9BFF7470206Q41932903-55068D94-9279-417C-8332-B33891748FBDQ43745575-17B3850A-E690-461C-A9D7-32CCEE93EBF2Q48259698-B1923C52-900F-43B4-BB1E-06866AFF4A1CQ49981154-714D1B7E-BCA8-4454-B4D1-710A603C0BCCQ56576062-9B01C4B6-0035-409A-84A2-186319BA2B5D
P2860
Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Incidence, risk factors, and o ...... nic graft-versus-host disease.
@en
type
label
Incidence, risk factors, and o ...... nic graft-versus-host disease.
@en
prefLabel
Incidence, risk factors, and o ...... nic graft-versus-host disease.
@en
P2093
P2860
P1433
P1476
Incidence, risk factors, and o ...... nic graft-versus-host disease.
@en
P2093
Effie W Petersdorf
J Lee Nelson
John A Hansen
Mary E D Flowers
Paul A Carpenter
Paul J Martin
Stephanie J Lee
Yoshihiro Inamoto
P2860
P304
P356
10.1182/BLOOD-2012-10-464198
P407
P577
2013-04-01T00:00:00Z